Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET
Company Participants
Andrew McKibben – SVP, Strategic Finance and IR
Chris Peetz – CEO
Peter Radovich – President and COO
Eric Bjerkholt – CFO
Conference Call Participants
Gavin Clark-Gartner – Evercore
Jessica Fye – JPMorgan
Selena Zhang – Morgan Stanley
Ryan McElroy – Leerink Partners
David Lebowitz – Citi
Ryan Deschner – Raymond James
Luke Herrmann – Baird
Catherine Novack – Citizens
Operator
Hello and welcome to Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results. My name is Carla, and I’ll be coordinating your call today. [Operator Instructions]
I would now like to hand you over to Andrew McKibben, Senior Vice President of Strategic Finance and Investor Relations to begin. Andrew, please go ahead when you’re ready.
Andrew McKibben
Thanks Carla, and good afternoon everyone. I’d like to welcome you to Mirum Pharmaceuticals’ first quarter 2025 conference call.
I’m joined today by our CEO, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; Eric Bjerkholt, our Chief Financial Officer. Joanne Quan, our Chief Medical Officer could not be with us today as she’s at an medical conference in Europe.
Earlier today, Mirum issued a news release announcing the company’s results for the first quarter 2025. Copies of this news release and SEC filings can be found in the Investors’ section of our website.
Before we start, I’d like to remind you that during the course of this conference call, we will be making certain forward-looking statements based on management’s current expectations, including statements regarding Mirum’s programs and market opportunities for its approved medicines and product candidates.
These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. We are under
Credit: Source link
